Team:Oxford/P&P intellectual property1

<html>
<head>
  <meta name="generator" content="HTML Tidy for Linux (vers 25 March 2009), see www.w3.org">
  <style type="text/css">

  @import url(http://fonts.googleapis.com/css?family=PT+Serif|Open+Sans:300italic,400,300);

  /* Enforce a lack of horizontal scrollbar so that the social section doesn't mess with the viewport. */
  html, body {
    max-width: 100%;
    overflow-x: hidden;
  }

  body {
    background-color: #EBEBEB; 
    margin: 0px;
    padding: 0;
    border: 0;
    vertical-align: baseline;
    font-family: 'Open Sans', 'helvetica', sans-serif;
    font-size: 10px;
    font-weight: 300;
  }

  #content {
    border:none;
    width:100%;
    margin:0;
    padding:0;
    background:none;
  }

  #catlinks {
    display:none;
  }

  #contentSub {
    display:none;
  }

  #menubar {
    width: auto;
    margin-top:0.5%;
}

  .left-menu:hover {
    background-color: transparent;
  }
  #menubar li a {
    background-color: transparent;
  }
  #menubar:hover {
    color: gray;
  }
  #menubar li a {
    color: #B5B5B5;
  }
  #menubar:hover li a {
    color: gray;
  }

  #menubar.left-menu.noprint ul li:last-child {
   display:none;
  }

  #search-controls {
    display:none;
  }

  #top-section {
    height:0px;
    width:100%;
    border:none;
  }

  #footer-box {
    border:none;
    display:none;
    width:100%;
  }

  #p-logo {
    display:none
  }

  .firstHeading {
  display:none;
  }

  #bodyContent p{
    display:none;
  }

  html, div, span, applet, object, iframe,
  h1, h2, h3, h4, h5, h6, p, blockquote, pre,
  a, abbr, acronym, address, big, cite, code,
  del, dfn, em, img, ins, kbd, q, s, samp,
  small, strike, strong, sub, sup, tt, var,
  b, u, i, center,
  dl, dt, dd, ol, ul, li,
  fieldset, form, label, legend,
  table, caption, tbody, tfoot, thead, tr, th, td,
  article, aside, canvas, details, embed, 
  figure, figcaption, footer, header, hgroup, 
  menu, nav, output, ruby, section, summary,
  time, mark, audio, video {
    margin: 0;
    padding: 0;
    border: 0;
    font-size: 100%;
    font: inherit;
    vertical-align: baseline;
  }

  #top-section {
    width: 965px;
    height: 0;
    margin: 0 auto;
    padding: 0;
    border: none;}

  .left-menu:hover {
    background-color: transparent;}

  #menubar li a {
    background-color: transparent;}

  .outer {  
    position:fixed;
    width:100%;
    height:100%;
  }

  img.supercoil {
    width:65%;
    display: block;
    margin-left: auto;
    margin-right: auto }

  .Heading {
    position:absolute;
    display: block;
  }















.pink_news_block {
      
        background: #FDDBDB;
        border-radius:15px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
width:96%;
}
.right_news_block {
      
        background: #FDDBDB;
        border-radius:15px; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
width:75%;float:right;line-height:150%;
}
.right_news_block2 {
      
        background: #FDDBDB;
        border-radius:15px; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
width:75%;float:right;line-height:150%;margin-top:2%;
}

.blue_news_block {
      
        background: #ADD8E6;
        border-radius:15px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:3%;padding-bottom:3%;
width:96%;
}

.orange_news_block1 {
      
        background: #FA6800;
        border-radius:30px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
width:32%;
}

.orange_news_block2 {
      
        background: #FA6800;
        border-radius:30px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
width:96%;
}

.yellow_news_block {
      
        background: #FFFF06;
        border-radius:30px; margin-top:2%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
width:27%;
}
.white_news_block {
      
        background: #fff;
        border-radius:15px; margin-top:2%; margin-left: 0%; padding-left:2%;padding-right:2%;padding-top:2%;padding-bottom:2%;
width:96%;
}

h1 {
	font-size: 120%;
	font-weight: 400;
	font-family:Helvetica;
	margin-bottom: 2%;
        line-height:150%;
       
}
h1white {
	font-size: 230%;
	font-weight: 400;
	font-family:Helvetica;
        color:#fff;
        line-height:150%;
}
h1blue {
	font-size: 180%;
	font-weight: 400;
	font-family:Helvetica;
        color:#4747E5;
        line-height:150%;
        font-style: italic;
}
h1blue2 {
	font-size: 130%;
	font-weight: 400;
	font-family:Helvetica;
        color:#4747E5;
        line-height:150%;
}

h1blue3 {
	font-size: 100%;
	font-weight: 400;
	font-family:Helvetica;
        color:#4747E5;
        line-height:120%;
        font-style: italic;
}


h1black {
	font-size: 230%;
	font-weight: 400;
	font-family:Helvetica;
        line-height:150%;
}
h1grey {
	font-size: 280%;
	font-weight: 400;
	font-family:Helvetica;
        color:#615555;
        line-height:150%;
}

  </style>











  <script type="text/javascript">

  function iconleft(x) {
    x.style.left="6%";
  }
  function iconnormal(x) {
    x.style.left="9%";
  }
$(document).ready(function(){
  $("#arrowr").click(function(){
    $("#grey").animate({right:'-13%'}, "fast");
  });
});
$(document).ready(function(){
  $("#arrowl").click(function(){
    $("#grey").animate({right:'-9%'}, "fast");
  });
});

  </script>

  <title></title>
</head>

<body>
  <div class="outer" style="overflow-y: scroll; overflow-x: hidden;">



<div id="stuff" style="float:left;position:absolute;margin-left:200px;margin-right:100px; margin-top:50px;">

<img src="https://static.igem.org/mediawiki/2014/0/08/Oxigemradcamcrop.jpg" style="position:absolute; width:100%;min-width:100%;z-index:-1; border-radius:15px;"/>


<div style="background-color:#D9D9D9; opacity:0.7; z-index:5; margin-right:auto;margin-left:auto; Height:75px; width:60%;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; font-weight: 450;">
<div style="background-color:white; opacity:0.7; Height:75px; width:100%;margin-top:5px:margin-bottom:5px;min-width:300px;font-size:65px;font-family:Helvetica;padding-top:5px; color:#596C8A; font-weight: 450;"><br>Intellectual Property</div>
</div>
<br><br>



















<div class="white_news_block">
<img src="https://static.igem.org/mediawiki/2014/b/b7/OxiGEMBioeconomy_Quote.jpg" style="float:left;position:relative; width:100%;" />
<br><br><br><br><br><br><br><br><br><br><br><br>
</div>


<div class="white_news_block">
<img src="https://static.igem.org/mediawiki/2014/5/5c/OxiGEM_IP.jpg" style="float:right;position:relative; width:30%;" />	


Intellectual Property is an increasingly important and controversial aspect of scientific advance, and synthetic biology is perhaps the paradigmatic area illustrating the effects of this growing legal influence. When thinking about how teams could turn their ideas from iGEM projects into viable real-world solutions, we realized that intellectual property is a crucial area to address.
<br><br>
Our team has produced a report exploring how teams can approach this task and how iGEM intellectual property policy can make the transition easier.
<br><br>
We begin with a brief overview of current intellectual property law (specifically relevant to the UK) before progressing to look at the challenges this poses for the iGEM competition. A number of different approaches which iGEM might choose to adopt towards intellectual property are discussed and the pros and cons of each are assessed. We then asked a range of interested groups, including iGEM students, professionals, and the public, for their views before concluding with recommendations for addressing intellectual property concerns in iGEM. We offer our conclusions in the form of advice to students, to the iGEM foundation, and briefly explore how a change in the law could have consequences for iGEM. This advice is purely based on our own views and our research which we hope will make interesting food for thought - it is not professional legal advice and should not be relied on as such!
</div>


<div class="white_news_block">
<center><iframe src="http://files.flipsnack.com/iframe/embed.html?hash=ft9yds58&wmode=transparent&t=1409550085" width="854" height="480" seamless="seamless" scrolling="no" frameborder="0" allowtransparency="true"></iframe></center>
</div>

<div class="white_news_block">
<h1blue2>Team Policy</h1blue2>
<br><br>
Dealing with intellectual property is not only necessary on a competition-wide level - each team must also make decisions as to how they wish to deal with the intellectual property they will acquire during the course of their project. Deciding whether to file a patent application can be a tricky decision - below are just some of the factors you might want to take into consideration…

<img src="https://static.igem.org/mediawiki/2014/8/84/OxigemIP_Flowchart2.jpg" style="float:left;position:relative; width:100%;" />

<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
</div>



<div class="white_news_block">
<h1blue2>Attitudes Survey</h1blue2>
<br><br>
We conducted a survey of attitudes within iGEM teams to intellectual property. The results, illustrated below, are analysed in detail in our report. Broadly, we found a noticeable lack of understanding of IP issues, confirming in many ways the findings and excellent foundation work done by British Columbia iGEM team in 2012, and a great deal of social mindedness in the responses.

</div>








<html>
<!-- Timeline script adapted from http://www.csslab.cl/2011/08/18/jquery-timelinr/.  Thanks!! -->

	<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

	<link rel="stylesheet" href="
http://www.hcs.harvard.edu/~stahr/javascript/style.css" type="text/css" media="screen" />

<!-- Extra custom css -->
<style type="text/css">
.issuedate
{
color: #021E6B;
background: none;
font-weight: normal;
margin-right: 50px;
padding-top: .5em;
padding-bottom: .17em;
border-bottom: none;	
font-size:150%;
line-height:130%;
}

#dates .iGEM14 {
			        font-size: 20px;
				}

</style>
	<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.6.2/jquery.min.js" type="text/javascript"></script>

	<script src="http://www.hcs.harvard.edu/~stahr/javascript/jquery.timelinr-0.9.3.js" type="text/javascript"></script>

	<script type="text/javascript"> 

		$(function(){

			$().timelinr({

				datesSpeed: 800,
				issuesSpeed: 800,
                                issuesTransparency: 1.0,
				arrowKeys: 'true',

			})

		});

	</script>

<!-- End timeline -->


<style type="text/css">
#ip_quote
{
  margin-top:10px;
  margin-bottom:10px;
  margin-left:auto;
  margin-right:auto;
  width:auto;
  color:#021E6B;
  font-size:120%;
  line-height:120%;
  text-align:justify;
}
</style>
</html>

<div class="whitebox">

__NOTOC__

<div class="white_news_block">
<html>
<center><a href="https://static.igem.org/mediawiki/2014/3/39/OxiGEM_Public_Survey.pdf">CLICK HERE TO DOWNLOAD A COPY OF OUR INTELLECTUAL PROPERTY SURVEY IN PDF FORMAT</a></p></center>
</html>
<div class="whitebox">

<html>
<!-- BEGIN TIMELINE WHITEBOX HERE -->
<div name="zfhistory">
<div id="timeline">

		<ul id="dates">

			<li><a href="#" class="dateobject">- 1 -</a></li>

			<li><a href="#" class="dateobject">- 2 -</a></li>

			<li><a href="#" class="dateobject">- 3 -</a></li>

			<li><a href="#" class="dateobject">- 4 -</a></li>

			<li><a href="#" class="dateobject">- 5 -</a></li>

			<li><a href="#" class="dateobject">- 6 -</a></li>

			<li><a href="#" class="dateobject">- 7 -</a></li>

		</ul>

		<ul id="issues">

			<li id="#- 1 -">

				<center><img src="https://static.igem.org/mediawiki/2014/5/5d/Experience_Chart.jpg" width="670" height="283" /></center>

				<div class="issuedate">What is your primary source of information about synthetic biology?</div>

				<p>As we can see, </p>

			</li>

			<li id="#- 2 -">

				<img src="https://static.igem.org/mediawiki/2014/a/a0/Application_Chart.jpg" width="670" height="283" />

				<div class="issuedate">How would you rate the quality of this information?</div>

				<p>The respondents rated information highly for accuracy (although perhaps this is to be expected as it is unlikely one would continue to read information from a source which regularly got the facts wrong). Relevance also scored highly, showing that people feel synthetic biology has a sufficient impact on their lives that they ought to be kept informed about it. The high score for availability is likely due to the heavy reliance on online information, however it is probable that this reliance also contributes to the relatively low scores for independence and accessibility. The sources accessed by the public online may well not be aimed at laymen but intended to be read by students or professionals and so may contain a high level of technical detail not accessible to the lay public.</p>

			</li>

			<li id="- 3 -">

				<img src="https://static.igem.org/mediawiki/2014/c/ce/Commercial_Viability_Chart.jpg" width="480" height="283" />

				<p> <br>The majority of teams (85%) appear to feel that there is at least the possibility that their project could be turned into a viable business or project – this makes sense given that many teams seek to use their project as an opportunity to use synthetic biology to address a problem. </p>

			</li>

	<li id="#- 4 -">

				<img src="https://static.igem.org/mediawiki/2014/c/cf/OxiGEMBenefit_to_Society.jpg" width="373" height="280" />

				<p>Again this chart shows how few teams believe their project is relevant to society. There was a split, slightly skewed towards commercial investment, in terms of the favoured means of funding, although it should be noted that many participants selected more than one option, suggesting mixed feelings and uncertainty on this question. Donation to the public domain was a popular option, indicating that many students support the BioBrick agreement and are keen to contribute their parts to it. </p>

			</li>

			<li id="#- 5 -">

				<img src="https://static.igem.org/mediawiki/2014/6/6c/OxiGEMIP_UNderstanding.jpg" width="405" height="280" />


				<p>Responses to this question support the need for guidance for iGEM teams on IP issues. Possible explanations for this the larger than expected (29%) group selecting 'adequate' include: evidence of a Drunning-Kruger effect whereby people overestimate their level of knowledge; underestimating the significance and relevance of intellectual property law to synthetic biology; or a genuinely adequate understanding amongst students. </p>

			</li>

			<li id="#- 6 -">

				<center><img src="https://static.igem.org/mediawiki/2014/2/20/Patentability_Views_Graph.jpg" width="685" height="287" /></center>

			</li>

			<li id="#- 7 -">

				<center><img src="https://static.igem.org/mediawiki/2014/d/d2/OxigemPriorities_Chart.jpg" width="500" height="287" /></center>
<p> <br> The graph below shows that profit is the least important considerations to students, but all others ranked more or less equally overall. The most important factor overall was benefit to society.</p>


			</li>

		</ul>

		<div id="grad_left"></div>

		<div id="grad_right"></div>

		<a href="#" id="next">+</a>

		<a href="#" id="prev">-</a>

	</div>



</div>
</div>

<!-- END TIMELINE WHITEBOX HERE -->

</div>











<div class="white_news_block">
<h1blue2>Young Synthetic Biologists Intellectual Property Workshop</h1blue2>
<br><br>
<img src="https://static.igem.org/mediawiki/2014/9/9a/OxiGEMYSB_Logo.jpg" style="float:right;position:relative; width:30%;" />
In the process of putting together our report and our guidance for iGEM teams, our team, in collaboration with the event organisers Philipp and Bethan of UCL iGEM, ran an intellectual property workshop at the Young Synthetic Biologists Conference 2.0 for other iGEMmers interested in the issue. The event was a great success; teams attending said 'I hadn't really appreciated just how big an impact this area of law could have on scientific development and particularly on synthetic biology - it's given me a lot to think about!'. We had a great time and there were some really interesting and insightful debates and comments - thanks especially to iGEM Cambridge for their passion on this topic!
<br><br>

<img src="https://static.igem.org/mediawiki/2014/7/71/YSB_Workshop.jpg" style="float:left;position:relative; width:33%;" />
<img src="https://static.igem.org/mediawiki/2014/3/33/OxiGEMYSB_Presentation.jpg" style="float:left;position:relative; width:33%;" />
<img src="https://static.igem.org/mediawiki/2014/8/84/YSBAdvert.jpg" style="float:right;position:relative; width:33%;margin-bottom:5.5%;" />

<br><br><br><br>
Another team member stated, 'I don't think our team had really put much thought into the IP ownership of our project - it's definitely something we should consider though, as we would want to be able to stop anyone using our project for potentially harmful research'. 'I always thought IP was kind of a binary question - you either patent something, or you give it away. But there are so many options in between. It's a very nuanced area of law, I think that's the main thing I hadn't really appreciated, there are lots of different ways you can share or protect your ideas'.
<br><br><br>
<h1blue2>View and download the Oxford iGEM powerpoint presentation used as the basis for our workshop below!</h1blue2>
<br><br><br>
<center><iframe style="border:none" src="http://files.photosnack.com/iframejs/embed.html?hash=ptjex0qe&t=1409913536" width="720" height="405" allowfullscreen="true" mozallowfullscreen="true" webkitallowfullscreen="true" ></iframe><center>


<br><br><br>
Special thanks for the success of this event are owed to:
<div class="list">
<li>Bethan  Wolfenden and Philipp Boeing for organising and iGEM UCL for hosting the YSB event</li>
<li>Andrew Russell, Glen Gowers, and Philipp Lorenz</li>
<li>Dundee, Cambridge, Edinburgh, and all the other teams which attended and took part in the debate!</li>
<li>...for his assistance with proof reading the presentation</li>
</div>

</div>







<div class="white_news_block">
<h1blue2> Government Policy </h1blue2>
<br><br>
Legislators have the difficult task of balancing a number of diverse and often conflicting intellectual property considerations. On the one hand, the government must incentivize innotvation - IP is an essential means of achieving this, as demonstrated by studies showing how patents can positively influence innovation by a margin of 15-25%<font style="vertical-align: super; font-size: 70%;">2</font> . 
<br><br>
The flipside of this is the responsibility of the government to prevent the creation of monopoly and to ensure that ideas are shared so as to maximize productive research. Again, there is research indicating that intellectual property is crucial to maintaining this balance, as some studies have expressed concerns that patents on initial discoveries may 'delay, hamper, or deter' innovations building on the patented work. The transaction cost of working with patented material is unattractive to many researchers, particularly individuals and start-ups.<font style="vertical-align: super; font-size: 70%;">3</font>.
<br><br>
Based on our research and our experiences during iGEM and in the field of IP, we believe that one of the most important roles for the government is to lead a new, more imaginative line of thinking about intellectual property protection, and to move away from analyzing these issues within the traditional and deeply engrained innovation vs. access dichotomy. 
<br><br>
Creating legal mechanisms to support this kind of innovative and flexible thinking about IP will be increasingly important to synthetic biology and to iGEM as the field grows increasingly complex and the dynamics between the many different interested parties continue to evolve. In order to successfully balance the demands of the public interest, investors, the environment, researchers, and inventors we will need to be more open minded when considering how to deal with IP in the future. It will not suffice to simply ask whether 'to patent or not to patent' and suppose that this is the extent of the available options. 
<br><br>
A further issue which we believe needs to be addressed by a change in the law is the current incapacity of the law to provide protection for computer code and algorithms. This is an issue which extends far beyond iGEM. Counter-intuitively, the lack of protection for algorithms means that this information can justifiably be kept secret rather than being visible and accessible to the public and/or regulators. The danger of this situation was demonstrated only recently by Facebook's so called 'social experiment' during which the company controlled the newsfeed content of users in an attempt to manipulate their emotions. Jim Sheridan, a member of the Commons Media Select Committee, expressed his 'worries about the ability of Facebook and others to manipulate people's thoughts in politics or other areas', and stressed the need for legislation in this area. 
<br><br>
Similarly, some form of protection for computer algorithms might allow models relevant to the iGEM competition (and to synthetic biology more broadly) to be shared in a similar way to BioBricks. Engineer Leroy Lim, responsible for some of the modeling aspect of the project, commented that it would have been highly useful to have models from previous years available at the beginning of the project. 'People would be far more likely to share their code and collaborate on this if we thought we'd get credit for our work...with companies it's even worse, there's no option but to keep your code to yourself because there's nothing else stopping competitors from taking everything you've developed and taking away your business'.

</div>












<div class="white_news_block">
<h1blue2> iGEM policy </h1blue2>

<br><br>
Given its ever increasing prominence in the field of synthetic biology and its unavoidable influence on the future of the field, iGEM cannot remain neutral on the matter of intellectual property. In the words of iGEM start-up Morph Bioinformatics, <h1blue3>“iGEM must position itself and not only define its role in the world of biotech - but also how it sees the role of synbio”.</h1blue3> 
<br><br>
iGEM’s approach to intellectual property will be intrinsically related to its overall position and self-definition in this exciting emerging field. <h1blue3>“It is time now to rationalize this 'big picture' and find a business model by treating the public, academia, biotech, pharma etc. as different units to optimize and synergize their outputs. And as with all business and communities, the major factor of success is to follow one ultimate vision - and that should remain increasing the quality of life”.</h1blue3> 
<br><br>
iGEM’s approach to intellectual property being critical for the future of the competition, its teams, and even the future of synthetic biology, our report analyses three alternative approaches to iGEM in dealing with this legal issue. 
<br><br>
The benefits and disadvantages of each are summarised in the tables below.: maintaining the status quo; complete openness; confidentiality clauses; reach through licence agreements.
<br>
<img src="https://static.igem.org/mediawiki/2014/d/d6/Oxford_the_status_quo.png" style="float:left;position:relative; width:100%;" />
<br>
<img src="https://static.igem.org/mediawiki/2014/6/61/OxiGEM_Confidentiality.jpg" style="float:left;position:relative; width:100%;" />
<br>
<img src="https://static.igem.org/mediawiki/2014/f/f4/OxiGEM_Openness.jpg" style="float:left;position:relative; width:100%;" />
<br>
<img src="https://static.igem.org/mediawiki/2014/e/e6/OxiGEM_RTLA.jpg" style="float:left;position:relative; width:100%;" />
<br>
Oxford iGEM 2014
</div>
<br>

















<div class="white_news_block">




<a href="https://2014.igem.org/Team:Oxford/policy_and_practices">
<img src="https://static.igem.org/mediawiki/2014/3/33/Oxford_P%26P1.png" style="float:left;position:relative; width:12%;" /></a>

<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/3/33/OxiGEMProblem_Solving.png" style="float:left;position:relative; width:12%; margin-left:2.66%;" /></a>

<a href="https://2014.igem.org/Team:Oxford/P&P_environmental_impact"><img src="https://static.igem.org/mediawiki/2014/7/75/Oxford_P%26P2.png" style="float:left;position:relative; width:11.8%; margin-left: 2.66%" /></a>





<a href="https://2014.igem.org/Team:Oxford/P&P_intellectual_property"><img src="https://static.igem.org/mediawiki/2014/0/00/Oxford_P%26P4.png" style="float:left;position:relative; width:12%;margin-left: 2.66%;" /></a>

<a href="https://2014.igem.org/Team:Oxford/P&P_communication">
<img src="https://static.igem.org/mediawiki/2014/4/43/Oxford_P%26P5.png" style="float:left;position:relative; width:13%; margin-left: 2.5%" /></a>

<a href="https://2014.igem.org/Team:Oxford/P&P_public_engagement"><img src="https://static.igem.org/mediawiki/2014/3/32/Oxford_P%26P6.png" style="float:left;position:relative; width:12%; margin-left: 2.66%;" /></a>

<a href="https://2014.igem.org/Team:Oxford/P&P_igem_europe">
<img src="https://static.igem.org/mediawiki/2014/9/92/Oxford_P%26P7.png" style="float:right;position:relative; width:12%;" /></a>

<br><br><br><br><br><br><br><br><br>
</div>
</div>














































<div id="sponsors" style="height:200px; width:100%;"></div>

</div>




<img src="https://static.igem.org/mediawiki/2014/9/91/OxigemSidebar.png" style="float:left;position:fixed; height:100%;" />



   <div class="iGEMlogo" style="width:6.5%; position:absolute; top:0.7%; right:0.5%; min-width:50px;">
    <a href="https://2014.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2014/9/98/OxigemiGEM.png" style="width:100%"/></a>
   </div>
   <a href="#"><img id="arrowl" src="https://static.igem.org/mediawiki/2014/7/77/OxigemArrowl.png" style="position:absolute; width:2.5%; top:50%;right:1.5%; opacity:0.6; z-index:4;" /></a>
   <div id="grey" style="width:14%; position:absolute; top:23%; right:-13%; z-index:4;">
    <img src="https://static.igem.org/mediawiki/2014/0/0d/OxigemGrey.png" style="position:relative;width:100%;" />
    <a href="#"><img id="arrowr" src="https://static.igem.org/mediawiki/2014/0/03/OxigemArrowr.png" style="position:absolute;width:16%;top:5%;left:10%;"></a>
    <div class="fbicon" style="position:absolute;width:23%; top:20%; left:9%;" onmouseover=
      "iconleft(this)" onmouseout="iconnormal(this)" border="0"><a href="https://www.facebook.com/oxfordigem" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/8/88/OxigemIconfacebook.png" style="width:100%;" /></a>
    </div>   
   <div class="twicon" style="position:absolute;width:23%; top:35%; left:9%;" onmouseover=
      "iconleft(this)" onmouseout="iconnormal(this)" border="0">
    <a href="https://twitter.com/OxfordiGEM" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/3/3d/OxigemIgemtwitter.png" style="width:100%;" /></a>
   </div>
   <div class="yticon" style="position:absolute;width:23%; top:50%; left:9%;" onmouseover=
      "iconleft(this)" onmouseout="iconnormal(this)" border="0">
    <a href="https://www.youtube.com/channel/UCx1QJHqQcZ09aT97V2f4Xdw" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/e/ea/OxigemIconyoutube.png" style="width:100%;" /></a>
   </div>
   <div class="oxicon" style="position:absolute;width:23%; top:65%; left:9%;" onmouseover=
      "iconleft(this)" onmouseout="iconnormal(this)" border="0">
    <a href="http://www.ox.ac.uk" target="_blank"><img src="https://static.igem.org/mediawiki/2014/8/8d/Iconoxford.png" style="width:100%;" /></a>
   </div>
   <div class="mailicon" style="position:absolute;width:23%; top:80%; left:9%;" onmouseover=
      "iconleft(this)" onmouseout="iconnormal(this)" border="0" >
    <a href="mailto:oxfordigem@bioch.ox.ac.uk" target="_blank" style="background-image: none;"><img src="https://static.igem.org/mediawiki/2014/3/35/OxigemIconmail.png" style="width:100%;" /></a>
   </div>

</body>
</html>